Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading

WIPO General Assembly 2026: KEI statement on the Committee on Development and Intellectual Property (CDIP)

On Tuesday, 14 July 2026, Knowledge Ecology International (KEI) delivered the following statement on agenda item, 11(iv), Report from the Committee on Development and Intellectual Property (CDIP) and Review of the Implementation of the Development Agenda Recommendations. For development, measures… Continue Reading

KEI Comments on NIH Exclusive License to OncoVanta for Cell Therapies for Cancer

On May 20, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment… Continue Reading